The PRECESTO clinical trial shows a clinically relevant reduction in smoking satisfaction in smokers not trying to quit with a more lasting effect than expected. The therapeutic potential of NFL-101 is reinforced.
To maximize the exploitation of the results of CESTO II, the management of NFL Biosciences intends to remain blinded during the 12 months of follow-up. The results of CESTO II would then be communicated in July 2024 without there being any preliminary communication in the 4th quarter of 2023. This proposal is subject to validation at the Board of Directors meeting on October 5, 2023.
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces the obtaining, this Thursday, September 21, of the results of the PRECESTO study which aimed to better describe the effect of NFL-101. At the same time, management will propose during the Board of Directors meeting on October 5, 2023 to modify the strategy for communicating the results of CESTO II, by maintaining blindness for the entire duration of the study. The results of CESTO II would be announced in July 2024.